Moxifloxacin: A potential new drug for shortening treatment of pulmonary TB?

Stephen H. Gillespie*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


TB requires treatment for at least 6 months with the standard regimen utilizing isoniazid, rifampicin, ethambutol and pyrazinamide. There is a pressing need for shorter regimens to improve adherence and completion rates. Moxifloxacin is highly active in vitro against Mycobacterium tuberculosis, is well absorbed with a wide volume of distribution. The drug is concentrated in lung tissue and in macrophages: important target sites for TB treatment. The excellent bactericidal activity data has been confirmed in animal models and Phase II studies. Animal experiments suggest that by using moxifloxacin to replace either ethambutol or isoniazid in the regimen, the duration of TB treatment could be shortened. This review summarizes the data that support the development of this drug into new treatment regimens.

Original languageEnglish
Pages (from-to)813-820
Number of pages8
Issue number6
Publication statusPublished - 1 Nov 2007


  • Bacterial load
  • Clinical trials
  • Early bactericidal studies
  • Pharmacokinetics
  • TB
  • Treatment regimens


Dive into the research topics of 'Moxifloxacin: A potential new drug for shortening treatment of pulmonary TB?'. Together they form a unique fingerprint.

Cite this